The consistent elevation of EDN1 in oxaliplatin-resistant and inherently insensitive CRC cells, coupled with functional validation through genetic manipulation, positions EDN1 inhibition as a promising strategy to resensitize tumors. This evidence concerns the gene EDN1 and colorectal carcinoma.